Table 2 Baseline characteristics of patients in this study

Sex

Male

184 (63)

65

49

14

41

15

Female

108 (37)

43

31

10

19

5

Race

Caucasian

162 (55)

57

48

20

30

7

Asian

38 (13)

15

9

0

14

0

African

6 (2)

2

1

0

2

1

Australian Aborigines

1 (0.5)

1

0

0

0

0

Pacific Islander

7 (2.5)

4

2

0

1

0

Middle Eastern

14 (5)

6

4

0

2

2

Other

11 (4)

5

2

0

4

0

Unknown

53 (18)

18

14

4

7

10

Aetiology

Polycystic kidney disease

12 (4)

1

5

1

3

2

Diabetes type II

70 (24)

23

23

3

18

3

Diabetes type I

46 (16)

21

5

5

10

5

Focal Segmental Glomerular Sclerosis

31 (11)

12

4

4

7

4

Glomerular Nephritis

21 (7)

5

7

4

4

1

Hypertension

4 (1)

1

1

1

1

0

Idiopathic

2 (1)

1

0

0

1

0

Ig A disease

24 (8)

10

5

1

6

2

Reflux nephropathy

14 (5)

6

5

1

2

0

Other

17 (6)

7

8

1

1

0

Renal Calculus

2 (1)

1

1

0

0

0

Renovascular disease

10 (3)

4

4

1

1

0

Unknown

39 (13)

16

12

2

6

3

Diabetes

Yes

138 (47)

51

37

11

29

10

No

154 (53)

57

43

13

31

10

Ischaemic heart disease

Yes

117 (40)

50

24

7

26

10

No

148 (51)

48

48

15

30

7

Unknown

27 (9)

10

8

2

4

3

Parathyroidectomy

Yes

17 (6)

6

2

1

7

1

No

275 (94)

102

78

23

53

19

Mean (SD)

Age (year)

65.56 (14.40)

67.51 (13.90)

66.33 (14.82)

66.29 (16.31)

62.06 (13.39)

61.83 (15.50)

Haemodialysis period (month)

49.22 (39.65)

46.52 (40.58)

47.86 (39.74)

75.25 (40.79)

49.06 (35.56)

38.10 (15.56)

Urea Reduction Ratio

72.76 (6.96)

71.76 (8.08)

73.93 (6.20)

75.30 (6.51)

71.99 (6.07)

73.30 (5.21)

Follow-up duration (month)

15.54 (3.98)

15.22 (4.22)

16.12 (3.15)

16.02 (3.29)

16.39 (3.37)

15.47 (4.14)